CONTEXT: Conference presentation of a real-world feasibility study in NSCLC treatment with afatinib and the impact of NRG1 fusions.
IMPACT: Medium
READ TIME: 2 mins
Quality Level Mean [1 – 10, 10 highest]: 8
1. ““The data from this feasibility study support previous findings that NRG1 gene fusions are detectable in significant numbers in patients with NSCLC,” Ajeet Gajra, MD, vice president of Cardinal Health, and coinvestigators wrote in a poster presentation.”
2. “Previously, afatinib was shown to demonstrate responses with patients with NRG1 fusion–positive tumors, including those with NSCLC, suggesting that it may be a novel treatment option for this patient population.2 Currently, afatinib is being explored in NRG1 gene fusion–positive tumors in the prospective TAPUR (NCT02693535) and DRUP trials (NCT02925234).”
3. “In the cohort of patients who received another systemic therapy (n = 41) the prevalence of NRG1 fusions occurred in those with NSCLC (56%), followed by breast cancer (10%), pancreatic cancer (7%), cholangiocarcinoma (7%), CRC (7%), bladder cancer (7%), ovarian cancer (2%), and RCC (2%).”
4. “For most patients with NSCLC, NRG1 fusion testing was performed prior to receiving frontline treatment in the afatinib (n = 15) and other systemic treatment cohorts (n = 19).”
5. “SDC4 and CD74 were found to be the most commonly observed NRG1 fusion partners in patients with NSCLC in both the afatinib (n = 8 and 9, respectively) and other systemic therapy (n = 1 and 3, respectively) cohorts.”